new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp

Read important updated information from the FDA

You'll hear about a new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp.

It's based on evidence of an increase in death and cardiovascular events when these drugs are used to boost hemoglobin above 12 g/dL.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote